$30.9 Bn Point Of Care/POC/Rapid Diagnostic Market By Test, Platform, Mode, End User - Global Forecast To 2024 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 8, 2019--The “Point Of Care/POC/Rapid Diagnostic Market By Test, Platform, Mode, End User - Global Forecast To 2024” report has been added to ResearchAndMarkets.com’s offering.
The global point of care (POC) diagnostics market is expected to grow at a CAGR of 8% from 2018 to reach $30.9 billion by 2024
Factors such as high prevalence of infectious diseases, rising incidence of target diseases, need for rapid diagnostics, skilled staff shortages in diagnostic labs, growing preference for home healthcare/self-testing, and favorable government initiatives for the adoption of POC testing products are expected to fuel the growth of point of care diagnostics market during the forecast period.
Despite the significant advances in sanitation and medicine, infectious diseases still annually claim in excess of more than 15 million lives in recent years. Infectious diseases are now emerging or re-emerging almost every year; thus, accurate diagnostics play a critical role in clinical decision making, and in disease control, and prevention. Therefore, POC tests for infectious diseases are expected to witness the highest growth among all POC products during the forecast period.
The Lateral Flow Immunoassay (LFIA) technology is the most simple and successful rapid diagnostics testing platform. The development of LFIA tests for use in developing countries has been focused majorly on infectious diseases including HIV, Strep A/B, legionella, malaria, respiratory viruses, influenza, meningitis, filariasis, tuberculosis, measles, mumps, rubella, chlamydia, and gonorrhea. LFIA platforms have significantly impacted on the treatment of cardiac diagnosis as well. Therefore, based on platform, LFIA dominates the POC market and will continue to play an important role during the forecast period owing to the increasing prevalence of infectious diseases and growing adoption of lateral flow POC diagnostics as compared to lab tests.
Based on end user, home care/self-testing commanded the largest share of the global point of care diagnostics market. This segment is also expected to witness the highest CAGR during the forecast period owing to the mounting inclination for at home healthcare, growing focus on continuous and remote monitoring, and expanding need for rapid tests among home care users.
North America commanded the largest share of the global POC market, followed by Europe, Asia-Pacific (APAC), Latin America, and the Middle East & Africa. However, APAC is estimated to be the fastest growing region due to presence of significant patient pool especially in rural/remote areas with limited healthcare access, aging population, rising burden of chronic diseases and infectious diseases. In APAC, China provides lucrative growth opportunities for the point of care diagnostics market players.
Key Topics Covered:
1.1. Currency and Limitations
2. Research Methodology
2.1. Research Process
3. Executive Summary
4. Market Insights
126.96.36.199. Increasing Prevalence of Infectious Diseases
188.8.131.52. Growing Incidence of Target Diseases
184.108.40.206. Technological Advancements and New Products Launches
220.127.116.11. Rising Number of CLIA-Waived PoC Tests
18.104.22.168. Shortage of Skilled Laboratory Technicians
22.214.171.124. Increasing Funding/Investments For the Development of PoC Products
126.96.36.199. Presence of Stringent Regulatory Policies
188.8.131.52. Pricing Pressures Owing to Reimbursement Cuts and Budget Constraints
184.108.40.206. Increasing Number of Conferences and Events
220.127.116.11. Growth Opportunities in Emerging Markets
18.104.22.168. PoC Tests with Multiplexing Capabilities
22.214.171.124. Healthcare Transition Converting Lab Tests to PoC Tests
126.96.36.199. Lack of Knowledge About the Use of PoC Devices
188.8.131.52. High Cost of PoC Devices
4.2. Regulatory Analysis
4.2.1. North America
4.2.4. Latin America, Middle East & Africa
4.3. Supply Chain Analysis
4.4. Pricing Analysis
4.5. Market Share Analysis
5. Point of Care Diagnostics Market, by Product
5.2. Blood Glucose Monitoring Testing Products
5.2.3. Lancets & Lancing Devices
5.3. Cardiac Metabolism Monitoring Testing Products
5.3.1. Blood Gas/Electrolytes Testing Products
5.3.2. Cardiac Markers
5.3.3. Hba1c Testing Products
5.4. Infectious Disease Testing Products
5.4.1. Influenza Testing Products
5.4.2. HIV Testing Products
5.4.3. Hepatitis C Testing Products
5.4.4. Sexually Transmitted Disease (STD) Testing Products
5.4.5. Healthcare Associated Infection (HAI) Testing Products
5.4.6. Respiratory Infection Testing Products
5.4.7. Tropical Disease Testing Products
5.4.8. Other Infectious Disease Testing Products
5.5. Coagulation Monitoring Products
5.5.1. Prothrombin Time (PT/INR) Testing Products
5.5.2. Activated Clotting Time (ACT/aPTT) Testing Products
5.6. Pregnancy and Fertility Testing Products
5.6.1. Pregnancy Testing Products
5.6.2. Fertility Testing Products
5.7. Fecal Occult Testing Products
5.8. Hematology Testing Products
5.9. Tumor/Cancer Markers Testing Products
5.10. Drugs of Abuse Testing Products
5.11. Urinalysis Testing Products
5.12. Cholesterol Testing Products
5.13. Other PoC Testing Products
6. Point of Care Diagnostics Market, by Platform
6.2. Lateral Flow Assays (Immunochromatography Tests/Lateral Flow Immunoassays)
6.5. Molecular Diagnostics
7. Point of Care Diagnostics Market, by Mode
7.2. Prescription-Based Testing Products
7.3. Over-the-Counter (OTC) Testing Products
8. Point of Care Diagnostics Market, by End User
8.2. Home Care/Self Testing
8.3. Physician offices & Outpatient/Ambulatory Care Settings
8.5. Research Laboratories
9. Point of Care Diagnostics Market, by Geography
9.2. North America
9.5.1. Latin America
9.5.2. Middle East & Africa
10. Company Profiles (Business Overview, Financial Overview, Products Portfolio, Strategic Developments)
10.1. Abbott Laboratories
10.2. AccuBioTech Co., Ltd.
10.3. Becton, Dickinson, and Company (BD)
10.4. Chembio Diagnostic Systems, Inc.
10.5. Danaher Corporation
10.6. EKF Diagnostics Holdings plc
10.7. WerfenLife, S.A.
10.8. Johnson & Johnson Services, Inc.
10.9. Nova Biomedical
10.10. F. Hoffmann-La Roche Ltd.
10.11. Sekisui Chemical Co. Ltd.
10.12. Quidel Corporation
10.13. Siemens AG
10.14. Trinity Biotech
For more information about this report visit https://www.researchandmarkets.com/research/dg982l/30_9_bn_point_of?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190308005129/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Point-of-Care Diagnostics
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/08/2019 04:55 AM/DISC: 03/08/2019 04:55 AM